產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
400-999-210024小時(shí)服務(wù)熱線
產(chǎn)品概述
名稱 | NK-92MI (人惡性非霍奇金淋巴瘤患者的自然殺傷細(xì)胞) (STR鑒定正確) |
別稱 | NK-92 MI; NK-92 mi; NK92-MI; NK92MI; NK-92 transfected with MFG-Hil2 |
種屬 | 人類 |
生長(zhǎng)特性 | 懸浮細(xì)胞 |
細(xì)胞形態(tài) | 淋巴母細(xì)胞樣 |
凍存條件 | 凍存液:90%FBS+10%DMSO 溫度:液氮 |
培養(yǎng)方案A(默認(rèn)) |
生長(zhǎng)培養(yǎng)基:
培養(yǎng)條件:
氣相:空氣,95%;CO2,5%, 溫度:37℃
|
推薦傳代比例 | 5×10^5-1×10^6cells/mL |
推薦換液頻率 | 2-3次/周 |
注意事項(xiàng) | 該細(xì)胞為懸浮細(xì)胞,請(qǐng)注意離心收集細(xì)胞懸液;請(qǐng)勿直接倒掉細(xì)胞培養(yǎng)液。 |
背景描述 | NK-92細(xì)胞是從一位患有急進(jìn)性非霍奇金淋巴瘤的50歲白人男性外周血單核細(xì)胞衍生來的一株IL-2依賴型NK細(xì)胞株。NK-92MI細(xì)胞是轉(zhuǎn)染得到的源自NK-92細(xì)胞的IL-2非依賴的NK細(xì)胞株。親本細(xì)胞NK-92通過微粒體基因轉(zhuǎn)化法用逆轉(zhuǎn)錄病毒MFG-hIL-2載體攜帶的人IL-2cDNA進(jìn)行轉(zhuǎn)化。可能由于載體整合到基因組DNA中,轉(zhuǎn)化是穩(wěn)定的。這株細(xì)胞對(duì)很多惡性細(xì)胞有細(xì)胞毒性;鉻釋放試驗(yàn)顯示它能殺死K562細(xì)胞和Daudi細(xì)胞。NK-92細(xì)胞有以下特征:CD2、CD7、CD11a、CD28、CD45、CD54表面標(biāo)記陽性;CD1、CD3、CD4、CD5、CD8、CD10、CD14、CD16、CD19、CD20、CD23、CD34和HLA-DR表面標(biāo)記陰性。其親本IL-2依賴的細(xì)胞株NK-92細(xì)胞及另一株同樣來源于NK-92細(xì)胞株的IL-2非依賴的細(xì)胞株NK-92CI都可從ATCC得到。NK-92MI細(xì)胞和NK-92CI細(xì)胞這兩個(gè)變種都包含、表達(dá)并合成hIL-2cDNA。NK-92MI細(xì)胞合成的IL-2水平比NK-92CI高,而親本細(xì)胞不合成表達(dá)。1998年9月提交到ATCC的培養(yǎng)物污染了支原體,其后代通過BM細(xì)胞周期蛋白處理21天消除支原體。處理后6周,用Hoechst染色、PCR和標(biāo)準(zhǔn)培養(yǎng)測(cè)試進(jìn)行支原體檢測(cè),結(jié)果都呈陰性。 |
年齡(性別) | 男性;50歲 |
組織來源 | 外周血 |
細(xì)胞類型 | 腫瘤細(xì)胞 |
腫瘤類型 | 淋巴瘤細(xì)胞 |
生物安全等級(jí) | BSL-2 |
保藏機(jī)構(gòu) | ATCC; CRL-2408 |
STR鑒定
-
STR位點(diǎn)信息
Amelogenin X,Y CSF1PO 11,12 D2S1338 19,20 D3S1358 15 D5S818 12,13 D7S820 10,11 D8S1179 12 D13S317 9,12 D16S539 11,12 D18S51 12,17 D19S433 14,15 D21S11 31.2,32 FGA 20,22 PentaD 10,12 PentaE 12 TH01 6,9.3 TPOX 8 vWA 18 D6S1043 11,12 D12S391 19 D2S441 14 -
STR鑒定圖
-
參考文獻(xiàn)
-
CRISPR knock-in of a chimeric antigen receptor into GAPDH 3’UTR locus generates potent B7H3-specific NK-92MI cells (2025-01-20)
期刊:CANCER GENE THERAPY
DOI:10.1038/s41417-025-00872-1
影響因子 :4.8
引用產(chǎn)品: NK-92MI 細(xì)胞
-
ATG-101 is a tetravalent PD-L1×4-1BB bispecific antibody that stimulates anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation (2024-03-19)
期刊:CANCER RESEARCH
DOI:10.1158/0008-5472.CAN-23-2701
影響因子 :12.5
引用產(chǎn)品: NK-92MI 細(xì)胞 , NK-92MI細(xì)胞專用培養(yǎng)基
-
HDAC Inhibition Increases CXCL12 Secretion to Recruit Natural Killer Cells in Peripheral T Cell Lymphoma (2024-05-08)
期刊:CANCER RESEARCH
DOI:10.1158/0008-5472.CAN-23-3250
影響因子 :11.2
引用產(chǎn)品: NK-92MI 細(xì)胞
-
CD70-specific CAR-NK cells expressing IL-15 for the treatment of CD19-negative B cell malignancy (2024-04-02)
期刊:Blood Advances
DOI:10.1182/bloodadvances.2023012202
影響因子 :7.5
引用產(chǎn)品: NK-92MI 細(xì)胞 , JeKo-1 細(xì)胞
-
Small-molecule inhibitor HI-TOPK-032 improves NK-92MI cell infiltration into ovarian tumours (2024-03-19)
期刊:BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
影響因子 :3.1
引用產(chǎn)品: McCoy's 5A 培養(yǎng)基 , RPMI-1640 培養(yǎng)基 , 青霉素-鏈霉素溶液 (雙抗),100× , MEMα 培養(yǎng)基 , NK-92MI 細(xì)胞
-
Wedelolactone induces natural killer cell activity and the improvement to bioavailability using polysaccharides from Ligustri Lucidi Fructus (2023-06-05)
期刊:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
DOI:10.1016/j.ijbiomac.2023.125208
影響因子 :8.2
引用產(chǎn)品: NK-92MI 細(xì)胞 , K-562 [K562] 細(xì)胞 , NK-92MI細(xì)胞專用培養(yǎng)基
-
NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions (2023-01-19)
期刊:Frontiers in Immunology
DOI:10.3389/fimmu.2022.1087689
影響因子 :7.3
引用產(chǎn)品: IOSE80 細(xì)胞 , NK-92MI 細(xì)胞
-
Single-cell profiling reveals immune disturbances landscape and HLA-F-mediated immune tolerance at the maternal-fetal interface in preeclampsia (2023-10-03)
期刊:Frontiers in Immunology
DOI:10.3389/fimmu.2023.1234577
影響因子 :7.3
引用產(chǎn)品: JAR 細(xì)胞 , NK-92MI 細(xì)胞
-
Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells (2023-03-01)
期刊:Frontiers in Pharmacology
DOI:10.3389/fphar.2023.1134895
影響因子 :5.6
引用產(chǎn)品: NK-92MI 細(xì)胞
-
EP3 enhances adhesion and cytotoxicity of NK cells toward hepatic stellate cells in a murine liver fibrosis model (2022-05-02)
期刊:JOURNAL OF EXPERIMENTAL MEDICINE
影響因子 :15.3
引用產(chǎn)品: NK-92MI 細(xì)胞
-
LncRNA NCAL1 potentiates natural killer cell cytotoxicity through the Gab2-PI3K-AKT pathway (2022-09-28)
期刊:Frontiers in Immunology
影響因子 :8.8
引用產(chǎn)品: NK-92MI 細(xì)胞
-
Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding (2021-10-19)
期刊:International Immunopharmacology
DOI:10.1016/j.intimp.2021.108195
影響因子 :5.7
引用產(chǎn)品: SK-Hep-1 細(xì)胞 , Hep G2 細(xì)胞 , NK-92MI 細(xì)胞 , NK-92MI細(xì)胞專用培養(yǎng)基
-
A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity (2021-01-01)
期刊:Biochemical And Biohysical Research Communicattons
DOI:10.1016/j.bbrc.2020.12.013
影響因子 :3.1
引用產(chǎn)品: NK-92MI 細(xì)胞
-
Acute lymphoblastic leukemia?derived exosome inhibits cytotoxicity of?natural killer cells by?TGF?β signaling pathway (2021-06-04)
期刊:3 BIOTECH
DOI:10.1007/s13205-021-02817-5
影響因子 :2.8
引用產(chǎn)品: Jurkat, Clone E6-1 細(xì)胞 , NK-92MI 細(xì)胞
FAQs
Q:{{item.question}}
A:
產(chǎn)品資料


識(shí)別碼示意圖